
Rznomics, a biopharmaceutical company specializing in RNA-based gene therapies, announced on the 24th that it has received a decision to grant a U.S. composition-of-matter patent for RZ-003, its gene therapy candidate targeting Alzheimer’s disease.
RZ-003 is an innovative RNA therapy engineered to edit and replace the APOE4 gene—the strongest genetic risk factor for Alzheimer's disease—transforming it into lower-risk variants such as APOE2 or APOE3ch (APOE3 Christchurch).
The apolipoprotein E (APOE) gene regulates the production of proteins responsible for lipid metabolism and transport across the body. Among its variants, the APOE4 genotype significantly drives Alzheimer’s risk by accelerating the accumulation of amyloid-beta plaques in the brain and disrupting the clearance of neurotoxic proteins.
The newly granted patent protects the composition of matter for the proprietary RNA replacement enzyme, which precisely cleaves and substitutes targeted sequences within APOE4 RNA. Crucially, the patent's broad coverage does not limit the specific type of therapeutic gene, delivery vehicle, or nucleic acid format (DNA or RNA). This versatile structural framework allows Rznomics to seamlessly expand its platform into future follow-on pipeline programs by combining various therapeutic genes and delivery mechanisms.
In tandem with its U.S. approval, Rznomics is actively securing global intellectual property rights, with parallel patent applications for RZ-003 currently under regulatory examination in major international markets, including Europe, Japan, and China.
CEO Lee Sung-wook stated, “Securing the composition-of-matter patent for RZ-003 in the United States substantially strengthens the global intellectual property portfolio for our proprietary RNA replacement enzyme platform.”
